scholarly journals O3B.6 The economic burden of work-related asbestos exposure

2019 ◽  
Vol 76 (Suppl 1) ◽  
pp. A25.1-A25
Author(s):  
Emile Tompa ◽  
Christina Kalcevich ◽  
Christopher McLeod ◽  
Martin Lebeau ◽  
Chaojie Song ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Economic Burden ◽  
Lifetime Cost ◽  
Asbestos Exposure ◽  
Indirect Costs ◽  
Policy Decision ◽  
Quality Adjusted Life Year ◽  
Newly Diagnosed

The objective of this study was to estimate the economic burden of lung cancer and mesothelioma due to occupational and paraoccupational asbestos exposure in Canada.We estimated the lifetime cost of newly diagnosed lung cancer and mesothelioma cases associated with occupational and para-occupational asbestos exposure for calendar year 2011 based on the societal perspective. The key cost components considered were healthcare costs, productivity and output costs, and quality of life costs.There were 427 cases of newly diagnosed mesothelioma cases and 1904 lung cancer cases attributable to asbestos exposure in our reference year—calendar year 2011—for a total of 2331 cases. Our estimate of the economic burden is $C831 million in direct and indirect costs for newly identified cases of mesothelioma and lung cancer and $C1.5 billion in quality of life costs based on a value of $C100,000 per quality-adjusted life year. This amounts to $C356,429 and $C652,369 per case, respectively.The economic burden of lung cancer and mesothelioma associated with occupational and para-occupational asbestos exposure is substantial. The estimate identified is for 2331 newly diagnosed, occupational and para-occupational exposure cases in 2011, so it is only a portion of the burden of existing cases in that year. Our findings provide important information for policy decision makers for priority setting, in particular the merits of banning the mining of asbestos and use of products containing asbestos in countries where they are still allowed and also the merits of asbestos removal in older buildings with asbestos insulation.

Asbestos Exposure Is Associated With A Poorer Quality Of Life In Patients With Lung Cancer

2012 ◽  
Author(s):  
Christophe Paris ◽  
Francis Guillemin ◽  
Amandine Luc ◽  
Christelle Clement-Duchene ◽  
Isabelle Thaon ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Asbestos Exposure

The association between the coronavirus disease 2019 (COVID-19) pandemic and quality of life and depression symptoms in patients with advanced lung cancer.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 12122-12122
Author(s):  
Lauren Heuer ◽  
Kathryn Elizabeth Post ◽  
Emily R. Gallagher ◽  
Chardria Trotter ◽  
Madeleine Elyze ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Regression Models ◽  
Advanced Lung Cancer ◽  
Depression Symptoms ◽  
Newly Diagnosed ◽  
Cancer Symptoms ◽  
Patients With Cancer ◽  
The Relationship

12122 Background: It is unclear whether patients with cancer experience greater distress as a result of the COVID-19 pandemic. Thus, we assessed the relationship of the COVID-19 pandemic with quality of life (QOL) and depression symptoms in patients newly diagnosed with advanced lung cancer. Methods: We conducted a cross-sectional study of patients with advanced lung cancer enrolled in two multisite randomized supportive care trials. We enrolled adult patients within 12 weeks of diagnosis of advanced lung cancer and an Eastern Cooperative Oncology Group (ECOG) Performance Status from 0 to 3 across 23 institutions in the United States. At the time of enrollment, participants completed the Functional Assessment of Cancer Therapy-Lung (FACT-L), which includes four wellbeing subscales (i.e., physical, social, emotional, and functional) as well as lung cancer symptoms, and the Patient Health Questionnaire-9 (PHQ-9) to assess their QOL and depression symptoms, respectively. We compared QOL and depression symptoms between participants enrolled prior to COVID-19 (i.e., those enrolled in the following time periods: March 2018 to January 2019 and March 2019 to January 2020) and during the COVID-19 pandemic (March 2020 to January 2021). We used linear regression models adjusting for age, race, gender, and time since diagnosis of advanced cancer to examine the relationship between the period of enrollment and patients’ QOL and depression symptoms. Results: A total of 860 patients were included in this analysis (665 participants enrolled prior to COVID-19 and 195 participants during COVID-19). The two cohorts did not differ significantly with respect to baseline demographic factors [Mean age 65.4 (SD = 11.4), 51.9% female]. In multivariate regression models, enrollment during COVID-19 was not associated with physical (B = -0.16, SE = 0.52, P = 0.763), social (B = -0.48, SE = 0.39, P = 0.217), emotional (B = -0.16, SE = 0.41, P = 0.693), functional (B = -0.83, SE = 0.55, P = 0.128) wellbeing, or lung cancer symptoms (B = -0.11, SE = 0.44, P = 0.806). Enrollment during COVID-19 was not associated with overall QOL (FACT-L: B = -1.32, SE = 1.69, P = 0.436) or depression symptoms (PHQ-9: B = -0.02, SE = 0.45, P = 0.973). Conclusions: Despite the prevailing belief that COVID-19 has negatively impacted QOL and distress in patients with cancer, we found no differences in QOL or depression symptoms in patients newly diagnosed with advanced lung cancer during the COVID-19 pandemic compared to those diagnosed prior to the pandemic. These findings suggest that factors other than the COVID-19 pandemic, such as patients’ experience with their cancer, contribute to their QOL and depression symptoms.

Quality of life in newly diagnosed patients with lung cancer in a developing country: is it important?

2006 ◽  
Vol 15 (3) ◽  
pp. 293-298 ◽  
Author(s):  
A. MOHAN ◽  
C. MOHAN ◽  
M. BHUTANI ◽  
A.K. PATHAK ◽  
H. PAL ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Developing Country ◽  
Newly Diagnosed

Quality of Life and Related Factors in Patients With Newly Diagnosed Advanced Lung Cancer: A Longitudinal Study

2014 ◽  
Vol 41 (2) ◽  
pp. E44-E55 ◽  
Author(s):  
Yu-Chien Liao ◽  
Shiow-Ching Shun ◽  
Wei-Yu Liao ◽  
Chong-Jen Yu ◽  
Pan-Chyr Yang ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Longitudinal Study ◽  
Advanced Lung Cancer ◽  
Newly Diagnosed ◽  
Related Factors

scholarly journals Clinical, humanistic, and economic burden of severe haemophilia B in adults receiving factor IX prophylaxis: findings from the CHESS II real-world burden of illness study in Europe

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Tom Burke ◽  
Sohaib Asghar ◽  
Jamie O’Hara ◽  
Margaret Chuang ◽  
Eileen K. Sawyer ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Real World ◽  
Economic Burden ◽  
Half Life ◽  
Burden Of Illness ◽  
Indirect Costs ◽  
Factor Ix ◽  
Severe Haemophilia ◽  
Haemophilia B

Abstract Background Real-world studies of the burden of severe haemophilia B in the context of recent therapeutic advances such as extended half-life (EHL) factor IX (FIX) products are limited. We analysed data from the recent CHESS II study to better understand the clinical, humanistic, and economic burden of severe haemophilia B in Europe. Data from male adults with severe haemophilia B receiving prophylaxis were analysed from the retrospective cross-sectional CHESS II study conducted in Germany, France, Italy, Spain and the United Kingdom. Inhibitors were exclusionary. Patients and physicians completed questionnaires on bleeding, joint status, quality of life, and haemophilia-related direct and indirect costs (2019–2020). All outcomes were summarised using descriptive statistics. Results A total of 75 CHESS II patients were eligible and included; 40 patients (53%) provided self-reported outcomes. Mean age was 36.2 years. Approximately half the patients were receiving EHL versus standard half-life (SHL) prophylaxis (44% vs 56%). Most patients reported mild or moderate chronic pain (76%) and had ≥ 2 bleeding events per year (70%), with a mean annualised bleed rate of 2.4. Mean annual total haemophilia-related direct medical cost per patient was €235,723, driven by FIX costs (€232,328 overall, n = 40; €186,528 for SHL, €290,620 for EHL). Mean annual indirect costs (€8,973) were driven by early retirement or work stoppage due to haemophilia. Mean quality of life (EQ-5D) score was 0.67. Conclusions These data document a substantial, persistent real-world burden of severe haemophilia B in Europe. Unmet needs persist for these patients, their caregivers, and society.

Sign in / Sign up

Export Citation Format

Share Document